Fig. 5: Transient exposure to CL17 or AREG is sufficient to promote peritoneal metastasis of CL31.

a Schematic depiction of experimental design of short-term supplementation with human recombinant AREG in vivo. b Representative H&E images of diaphragms collected from mice at the 10-week end point supplemented with AREG or BSA vehicle control as depicted in (a), representative images from one of two independent experiments. T tumor cells, D diaphragm, B bone. Scale bar, 2 mm. c Tumor burden score of solid metastases on the diaphragm generated by CL31 in mice treated with AREG or BSA vehicle control. Data from two independent experiments, total n = 8 mice. p Value was computed using the chi-square test with Monte Carlo simulation. d Fold change in luciferase activity in blood samples collected from individual mice at the end point (10 weeks) relative to the 24-h time point. Data from two independent experiments (total n = 8 mice) and shown as mean ± SD. p Value was computed using the Mann–Whitney test, two-tailed. NS not significant. e Representative H&E images of the diaphragms of mice inoculated with CL31 alone (3 × 10⁶ cells) or a 1:1 mixture of CL31 and CL17 (3 × 10⁶ total cells). T tumor cells, D diaphragm, L liver, B bone. Scale bar, 2 mm. f Tumor burden score of solid metastases on the diaphragm generated by the indicated cell inocula. Data from two independent experiments (total n = 6–7 mice) and shown as mean ± SD. p Values were computed using the chi-square test with Monte Carlo simulation. NS not significant. g Fold change in luciferase activity in blood samples collected from individual mice at the end point (10 weeks) relative to the 24-h time point. Data from two independent experiments (total n = 6–7 mice) and shown as mean ± SD. p Values were computed using the one-way ANOVA test and Dunnett’s multiple comparison test. NS not significant.